Scientific Publications

CLINICAL

Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans
Kim MK et al.,
Sci Transl Med 2013 May 15; 5(185): 185ra63.
doi: 10.1126/scitranslmed.3005361.
PMID: 23677592 [PubMed - in process]

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Heo J et al.,
Nature Medicine. 2013 Feb 10;19(3):329-36.
doi: 10.1038/nm.3089.
PMID:23396206 [PubMed - indexed for MEDLINE]

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Breitbach CJ et al
Cancer Res. 2013 Feb 15;73(4):1265-1275. Epub 2013 Feb 7
PMID:23393196 [PubMed - indexed for MEDLINE]

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA et al
Mol Ther. 2012 Apr;20(4):749-58. Epub 2011 Dec 20.
doi: 10.1038/mt.2011.276.
PMID:22186794 [PubMed - indexed for MEDLINE]
PMCID: PMC3321594

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Breitbach CJ et al.
Nature. 2011 Aug 31;477(7362):99-102.
doi: 10.1038/nature10358.
PMID: 21886163 [PubMed - indexed for MEDLINE]

Tumor-fighting virus homes in
Galanis E (Editorial)
Nature. 2011 Aug 31;477(7362):40-1.
doi: 10.1038/477040a
PMID: 21886153

Seek and destroy: oncolytic virus shows promise in phase I trial
Schmitt CA (Editorial)
Nature Reviews Clinical Oncology
Nature Review Clinical Oncology. 2011 Sep 20;8(11):630
doi: 10.1038/nrclinonc.2011.143.
PMID:21931354

Targeted Therapeutics
Editorial
Cell 147(2), 253, 2011 Oct 14
doi:10.1016/j.cell.2011.09.043

Oncolytic poxvirus homes in on cancer cells
Flemming A (Editorial)
Nature Review Drug Discovery. 2011 Oct 31;10(11):814
doi: 10.1038/nrd3589.
PMID: 22037035

An Intravenous Stimulus Package for Oncolytic Virotherapy<br /> Vile R and Melcher A (Editorial)
Molecular Therapy, 2011 Nov;19(11):1930-2.
doi: 10.1038/mt.2011.217.19
PMID: 22051602

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.
Hwang TH et al.
Molecular Therapy. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19.
PMID: 21772252

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Heo et al.
Molecular Therapy. 2011 Jun;19(6):1170-9. Epub 2011 Mar 22.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
Kirn DH and Thorne SH.
Nature Review Cancer. 9(1):64-71. 2009.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH, et al.
Lancet Oncology 9:533-42. 2008.

A smart move against cancer for vaccinia virus.
R. Alemany (Editorial)
Lancet Oncology 9:507-8. 2008.

Immunotherapeutic potential of oncolytic virotherapy.
R. Prestwich et al. (Editorial)
Lancet Oncology 9:610-12. 2008.

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.
Liu TC et al.
Molecular Therapy 16(9):1637- 42. 2008.

Fighting fire with fire: effects of oncolytic virotherapy on underlying viral hepatitis in hepatocellular carcinoma.
T. Reid (Editorial)
Molecular Therapy 16(9):1521-23. 2008.

PRECLINICAL

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH et al.
Cancer Gene Therapy. 17(2):73-9. 2010.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
Kim JH et al.
Molecular Therapy 14(3):533-42. 2006.

A pox on your tumor.
Editorial by David A. Williams, Editor-in-Chief
Molecular Therapy 14(3):313. 2006.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH et al.
Journal of Clinical Investigation. 117(11):3350-8. 2007

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Mastrangelo M, et al.
Cancer Gene Therapy 6: 409-422. 1998

OTHER REVIEW & EDITORIALS

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ et al.
Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72.
PMID: 21740365[PubMed - indexed for MEDLINE]


Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
Breitbach CJ et al.
Cytokine Growth Factor Review. 21(2-3):85-9. 2010.

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE et al.
Current Opinion in Investigational Drugs. 10(12):1372-82. 2009

Back to Top